Alias
科研级 Bococizumab ( 伯考赛珠单抗 ), Anti-PCSK9 Recombinant Antibody, Research Grade Bococizumab
Molecular Name
Bococizumab
Applications
FC, IP, ELISA, Neut, FuncS
Purity
≥95% as determined by SDS-PAGE
Buffer
Supplied in PBS, PH7.5
Target
PCSK9/NARC1/ PC9[Homo sapiens]
Sequence
Please contact our sales representative to learn more information about this reagents.
Background
Bococizumab (USAN, development code RN316) is a drug that was in development by Pfizer targeting PCSK9 to reduce LDL cholesterol. Pfizer withdrew the drug from development in November 2016, determining that it was "not likely to provide value to patients, physicians or shareholders."
Storage
该产品可在 2°C-8°C 下保存一个月,活性不会明显降低。在 -20°C 至 -80°C 下保存,可稳定保存十二个月。避免反复冻融,用冰袋运输。